Clinical Research Directory

Inclusion Criteria: * Participants with headaches that meet the diagnostic criteria for migraines according to the International Classification of Headache Disorders, 3rd edition (ICHD-3), with or without aura. * Patients prescribed rimegepant by the attending physician for the treatment of migraines. * Signed informed consent form. * Age greater than 18 years. * Not concurrently participating in other interventional clinical studies. Exclusion Criteria: * Patients diagnosed with secondary headaches. * Patients with severe visual, auditory, language, intellectual, memory, consciousness impairments or other conditions that prevent them from completing the questionnaire and follow-up. * Pregnant or lactating female patients. * Patients deemed by the investigator as unsuitable for participation in the study or unable to complete the 4-week follow-up. * Patients with a known history of hypersensitivity reactions to rimegepant or its components. * Evidence in the medical history suggesting the presence of uncontrolled or unstable cardiovascular diseases (such as ischemic heart disease, coronary artery vasospasm, or cerebrovascular ischemia), or a history of myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within the past 6 months before the screening visit.